Natixis Advisors, L.P. Intra Cellular Therapies, Inc. Transaction History
Natixis Advisors, L.P.
- $51.3 Billion
- Q3 2024
A detailed history of Natixis Advisors, L.P. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 24,583 shares of ITCI stock, worth $2.05 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,583
Previous 31,660
22.35%
Holding current value
$2.05 Million
Previous $2.17 Million
17.02%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ITCI
# of Institutions
379Shares Held
84.7MCall Options Held
319KPut Options Held
143K-
Vanguard Group Inc Valley Forge, PA9.63MShares$803 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$527 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$441 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$321 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$254 Million3.36% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $7.87B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...